A
Angel Artal
Researcher at University of Zaragoza
Publications - 75
Citations - 7121
Angel Artal is an academic researcher from University of Zaragoza. The author has contributed to research in topics: Lung cancer & Gemcitabine. The author has an hindex of 19, co-authored 73 publications receiving 6435 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
Felipe Cardenal,M. Paz López-Cabrerizo,Antonio Antón,Vicente Alberola,Bartomeu Massuti,Alfredo Carrato,Isidoro Barneto,M. Lomas,Margarita García,Pilar Lianes,Joaquín Montalar,C. Vadell,José Luis González-Larriba,Binh Bui Nguyen,Angel Artal,Rafael Rosell +15 more
TL;DR: Compared with etoposide-cisplatin, gemcitabine-c isplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC.
Journal ArticleDOI
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Rafael Rosell,Kathleen D. Danenberg,Vincente Alberola,Gerold Bepler,Jose Javier Sanchez,Carlos Camps,Mariano Provencio,Dolores Isla,Miquel Taron,Pilar Diz,Angel Artal +10 more
TL;DR: RRM1 mRNA expression is a crucial predictive marker of survival in gemcitabine/cisplatin-treated patients and can and should be used to personalize chemotherapy.
Journal ArticleDOI
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla,Carme Sarries,Rafael Rosell,Guillermo Alonso,Manuel Domine,Miquel Taron,Guillermo Lopez-Vivanco,Carlos Camps,M. Botia,L. Nuñez,Maria Sanchez-Ronco,Jose Javier Sanchez,Marta López-Brea,Isidoro Barneto,A. Paredes,B. Medina,Angel Artal,Pilar Lianes +17 more
TL;DR: ERCC1 SNP assessment could be an important component of tailored chemotherapy trials and patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival.
Journal ArticleDOI
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Vicente Alberola,Carlos Camps,Mariano Provencio,Dolores Isla,Rafael Rosell,C. Vadell,Isabel Bover,Ana Ruiz-Casado,P. Azagra,Ulpiano Jimenez,Jose-Luis Gonzalez-Larriba,Pilar Diz,Felipe Cardenal,Angel Artal,Alfredo Carrato,Serafin Morales,José Jurado Sánchez,R. de las Peñas,Enriqueta Felip,Guillermo Lopez-Vivanco +19 more
TL;DR: CG remains a standard regimen for first-line treatment of advanced NSCLC on the basis of results, and no differences in median survival or time to progression were observed.